Newstral
Genentech
- New jab could revolutionise bowel cancer treatment - and it is being used first in the West Midlandsexpressandstar.com
- Bowel cancer patient first in England to have personalised jab to fight diseaseexpressandstar.com
- Johnson & Johnson Data Breach Reported; Possibly Connected to Major Lash Group Data Breachjdsupra.com
- The Lash Group Notifies Consumers of Massive Data Breach Leaking Their Sensitive Medical Informationjdsupra.com
- The First Biosimilar Disputes at the Unified Patent Court (UPC)jdsupra.com
- A world without flu: Long-lasting drug blocks Influenza Anewatlas.com
- Federal Circuit Reiterates That an Alleged Infringer’s Intent Is Irrelevant in a Hatch-Waxman Safe Harbor Analysisjdsupra.com
- Biosimilar Launch and Approval Updates – Tyenne® (tocilizumab-aazg), Xlucane™ (ranibizumab), Hercessi™ (trastuzumab-strf)jdsupra.com
- STessier-Lavigne leads new AI biopharma startupstanforddaily.com
- Mind, Body, and Spiritual Well-Being for Women Addressed in NAACP Forum in Oaklandpostnewsgroup.com
- Genentech and Dr. Reddy’s Settle BPCIA Rituximab Litigationjdsupra.com
- Layoffs jolt Bay Area: Golden Gate Fields, Genentech, Intel ax hundredsSan Jose Mercury News
- Celltrion Submits aBLA for CT-P39, Proposed Interchangeable Biosimilar of Xolair® (omalizumab)jdsupra.com
- TLarge Bay Area Genentech facility purchased by Swiss firmthereporter.com
- A Novel Drug, A Protest, And The Fight To Prevent Breast Cancer DeathsForbes
- Fresenius Kabi Announces FDA Approval of TYENNE, a Tocilizumab Biosimilar Referencing ACTEMRAjdsupra.com
- Fresenius Kabi’s Actemra® biosimilar Tyenne® (tocilizumab-aazg) Approved in the U.S.jdsupra.com
- COpenAI’s Board Reshuffle: Altman Returns Amidst New Appointmentsceoworld.biz
Frequent names
Newstral's extraction of names of people and organisations from the world's news is completely automated. If you do not want your name to appear here, please contact us. We will be happy to look at your request.